broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K76210423-001-01-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.850472 | -2.337436 | 0.103434 | 0.928978 | 0.061263 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000984 |
BRD-K76239644-001-02-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.68833 | -3.827813 | 0.204726 | 0.806617 | 0.251432 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000984 |
BRD-K76674262-001-03-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.233463 | 11.513537 | 0.681502 | 0.723383 | 0.301349 | 0.318272 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000984 |
BRD-K76908866-001-07-6 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.716045 | -3.460782 | 0.083607 | 0.934533 | 0.005715 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000984 |
BRD-K78431006-001-15-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.091664 | 0.104025 | -0.009206 | 1 | 0.004306 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000984 |
BRD-K79254416-001-21-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.402984 | 0.953151 | 0.354811 | 1 | 0.034579 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000984 |
BRD-K81016934-001-02-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.950451 | -0.00113 | -0.05401 | 0.974923 | 189,150,119.174575 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000984 |
BRD-K81418486-001-44-2 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.196888 | 1.257162 | 0.729809 | 0.720452 | 0.344996 | 0.513702 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000984 |
BRD-K81473043-001-19-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 5.434852 | 0.295041 | 0.06537 | 1 | 5,571.714545 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000984 |
BRD-K82135108-001-04-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.108735 | -7.118766 | 0.041882 | 1 | 0.082655 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000984 |
BRD-K82818427-001-04-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.853925 | 2.302106 | -0.051401 | 0.917292 | 0.041081 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000984 |
BRD-K83029223-001-01-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 5.599923 | 0.14248 | 0.013194 | 1 | 797,147.172577 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000984 |
BRD-K83988098-001-02-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.232899 | 2.913946 | 0.633605 | 0.899499 | 0.044125 | 0.054718 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000984 |
BRD-K85402309-043-01-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.472141 | 0.077206 | -0.00807 | 0.760938 | 0.929355 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000984 |
BRD-K85606544-001-09-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.013871 | -2.96476 | -0.06374 | 1 | 131.090862 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000984 |
BRD-K86118762-001-01-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.603605 | 0.766555 | 0.063556 | 1 | 2.583942 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000984 |
BRD-K86972824-001-01-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.930322 | -0.008144 | -0.001796 | 0.964643 | 3.006674 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000984 |
BRD-K87737963-001-06-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.110473 | 1.631285 | 0.572764 | 0.850276 | 2.040805 | 2.378328 | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000984 |
BRD-K87782578-001-01-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.933999 | -0.11454 | -0.023849 | 0.948663 | 5,642.856905 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000984 |
BRD-K87909389-003-03-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.175453 | 2.617401 | 0.805614 | 0.65188 | 0.166184 | 0.196022 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000984 |
BRD-K88510285-001-17-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.153655 | 6.734356 | 0.493661 | 0.636021 | 0.038547 | 0.040707 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000984 |
BRD-K89014967-001-04-3 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.869086 | -2.109429 | 0.099603 | 0.914888 | 0.335427 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000984 |
BRD-K92441787-001-04-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.79268 | -0.476175 | 0.005963 | 0.909499 | 0.036734 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000984 |
BRD-K92723993-001-17-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 54.802859 | 0.182612 | -0.001354 | 1 | 446,662,204,777,070,340,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000984 |
BRD-K95142244-001-01-5 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.825406 | 0.885237 | 0.453498 | 1 | 0.526893 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000984 |
BRD-K96123349-236-02-8 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.407988 | 1.028165 | 0.397648 | 1 | 0.027099 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000984 |
BRD-K98572433-001-02-9 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.987023 | -0.758059 | -0.088061 | 0.994205 | 0.045225 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000984 |
BRD-K99113996-001-02-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 1.884088 | 3.03135 | 0.421988 | 1 | 0.231571 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000984 |
BRD-K99616396-001-05-1 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.835563 | -0.013636 | -0.005116 | 0.914938 | 12.510659 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000984 |
BRD-K99749624-001-07-0 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.918665 | -0.321653 | -0.022948 | 0.950286 | 0.41745 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000984 |
BRD-M97302542-001-04-4 | ACH-000984 | HEC6_ENDOMETRIUM | MTS010 | 1 | 0.90217 | 1.130551 | 0.015397 | 0.955118 | 0.11693 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000984 |
BRD-A25234499-001-19-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.98276 | -0.0368 | -0.040844 | 0.990954 | 1.154941 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000985 |
BRD-A70858459-001-01-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.419444 | 2.355723 | 0.341988 | 0.950183 | 4.637448 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000985 |
BRD-A74914197-001-02-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.402936 | 0.180801 | 0.044418 | 1 | 0.001357 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000985 |
BRD-K02113016-001-19-6 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.955945 | 1.390491 | 0.038913 | 0.974877 | 0.039423 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000985 |
BRD-K02130563-001-11-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.155208 | 3.755246 | 0.945228 | 0.614897 | 0.119873 | 0.132344 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000985 |
BRD-K03390685-001-01-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.434337 | 1.278253 | 0.741797 | 0.720963 | 0.083378 | 0.408112 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000985 |
BRD-K03406345-001-21-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.873919 | 0.230014 | -0.034477 | 0.92815 | 0.020314 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000985 |
BRD-K03449891-001-08-6 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.742017 | 0.003234 | -0.037239 | 0.877295 | 978,972,432,690.6184 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000985 |
BRD-K03765900-001-01-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.484655 | 0.789414 | 0.278916 | 1 | 0.013076 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000985 |
BRD-K05804044-001-18-5 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 146.294374 | -6.333102 | -0.046665 | 1 | 0.000155 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000985 |
BRD-K06814349-304-02-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.54554 | 3.246438 | 0.276187 | 0.809835 | 0.172347 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000985 |
BRD-K08109215-001-06-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.662043 | 0.362877 | 0.341579 | 0.856415 | 0.220544 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000985 |
BRD-K08542803-001-02-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.626892 | 0.160364 | -0.034964 | 0.802454 | 0.036077 | null | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000985 |
BRD-K08547377-001-04-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.837019 | 0.51317 | 0.064663 | 0.927171 | 0.143798 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000985 |
BRD-K08703257-001-13-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.210081 | -0.111094 | 0.029241 | 1 | 0.013936 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000985 |
BRD-K08799216-001-05-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.907266 | 1.141347 | 0.762303 | 1 | 0.057946 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000985 |
BRD-K09951645-001-11-8 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.939203 | 5.789498 | 0.113202 | 0.952163 | 0.004828 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000985 |
BRD-K11267252-001-05-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.354203 | 2.582523 | 0.398138 | 0.949801 | 4.991695 | 8.044458 | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000985 |
BRD-K11630072-001-13-2 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.867515 | 2.506874 | 0.105566 | 0.952828 | 0.315778 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000985 |
BRD-K12184916-001-19-6 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.818992 | 2.877332 | 0.130031 | 0.85801 | 0.004807 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000985 |
BRD-K12343256-001-14-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.168867 | 0.425935 | 0.776172 | 0.660382 | 0.247427 | 0.651062 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000985 |
BRD-K13049116-001-04-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.648928 | 0.058591 | -0.006883 | 0.825937 | 0.104208 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000985 |
BRD-K13390322-001-06-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.154304 | 2.291761 | 0.673811 | 0.660663 | 0.203649 | 0.239228 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000985 |
BRD-K13514097-001-04-6 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.70568 | 3.836247 | 0.467436 | 0.856577 | 0.088344 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000985 |
BRD-K13662825-001-07-5 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.124553 | 3.96886 | 0.729434 | 0.49699 | 0.009487 | 0.010197 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000985 |
BRD-K14109347-001-03-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.129459 | 4.814174 | 0.61279 | 0.865441 | 2.231542 | 2.374851 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000985 |
BRD-K15179879-001-03-2 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.158326 | 3.094013 | 0.840358 | 0.582083 | 0.080777 | 0.091355 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000985 |
BRD-K15600710-066-05-8 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.611646 | 5.719483 | 0.474492 | 0.860419 | 0.300069 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000985 |
BRD-K16730910-001-10-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.848829 | -1.047742 | -0.007775 | 0.974406 | 0.002614 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000985 |
BRD-K17555800-003-02-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.101411 | 0.321349 | -0.030222 | 1 | 0.00233 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000985 |
BRD-K17610631-001-03-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.681237 | 8.104933 | 0.330548 | 0.887588 | 0.316109 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000985 |
BRD-K17743125-001-08-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.09028 | 2.242867 | 0.572391 | 0.900791 | 3.62495 | 3.961514 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000985 |
BRD-K18961567-001-01-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.759134 | -1.505138 | 0.089354 | 0.954167 | 0.003705 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000985 |
BRD-K19540840-001-09-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.662161 | 5.869115 | 0.527696 | 1 | 0.918477 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000985 |
BRD-K19687926-001-04-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.395582 | 0.646392 | 0.181286 | 1 | 0.255075 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000985 |
BRD-K19796430-001-05-6 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.255907 | 0.095599 | 0.02556 | 1 | 0.064511 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000985 |
BRD-K22064724-001-01-8 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.128958 | 5.603193 | 0.671731 | 0.841359 | 1.707629 | 1.801 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000985 |
BRD-K22822991-001-02-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.132253 | -0.99424 | -0.009771 | 1 | 0.029226 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000985 |
BRD-K23228615-001-02-8 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.990386 | 0.008909 | -0.071927 | 0.995247 | 0.974182 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000985 |
BRD-K23984367-001-07-5 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.915227 | -0.053721 | -0.03558 | 0.951519 | 17.645777 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000985 |
BRD-K26026438-001-01-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.89002 | 0.11547 | -0.011739 | 0.929831 | 0.000509 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000985 |
BRD-K28822270-001-03-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.774144 | 1.459746 | -0.018373 | 0.909976 | 0.219234 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000985 |
BRD-K29905972-001-06-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.126171 | 0.387832 | 0.047604 | 1 | 0.0069 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000985 |
BRD-K30577245-001-05-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.220665 | -0.769623 | 0.002656 | 1 | 0.000036 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000985 |
BRD-K31698212-001-02-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.558624 | 0.686393 | -0.025086 | 1 | 12.461294 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000985 |
BRD-K31928526-001-02-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.117425 | 0.415986 | -0.028863 | 1 | 0.03246 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000985 |
BRD-K33379087-001-07-5 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 2.702633 | 2.227463 | 0.290866 | 1 | 12.846912 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000985 |
BRD-K33610132-001-02-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.155354 | -0.185761 | -0.085003 | 1 | 1.287006 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000985 |
BRD-K33622447-066-01-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.546266 | 0.765783 | 0.169748 | 0.824313 | 0.248267 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000985 |
BRD-K35520305-001-16-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.364824 | 0.293272 | 0.193175 | 1 | 0.128012 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000985 |
BRD-K36627727-001-05-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.067938 | 0.157729 | -0.001087 | 1 | 11.241593 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000985 |
BRD-K36788280-001-01-2 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.104954 | 0.545493 | -0.024773 | 1 | 0.013597 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000985 |
BRD-K37379014-001-02-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.955106 | -1.1409 | -0.038788 | 0.977422 | 0.001254 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000985 |
BRD-K38332599-001-01-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.661389 | 11.692777 | 0.561635 | 0.830786 | 0.078308 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000985 |
BRD-K38527262-300-01-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.5976 | 0.509849 | 0.237084 | 0.880577 | 0.812076 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000985 |
BRD-K38852836-001-02-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.18794 | 0.998905 | 0.694713 | 0.523028 | 0.008254 | 0.013232 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000985 |
BRD-K39974922-001-04-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.294868 | -0.310519 | -0.172577 | 1 | 0.067975 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000985 |
BRD-K41859756-001-06-8 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.282612 | 1.433811 | 0.582735 | 0.473075 | 0.001975 | 0.003531 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000985 |
BRD-K42495768-001-01-7 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.118358 | 0.009519 | -0.01233 | 1 | 0.012296 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000985 |
BRD-K42805893-001-04-9 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.57611 | 0.107219 | 0.023838 | 1 | 1.07004 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000985 |
BRD-K42828737-001-03-3 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.43208 | -0.377751 | 0.040516 | 1 | 0.005016 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000985 |
BRD-K42898655-001-01-8 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.881839 | 5.085263 | 0.104897 | 0.941564 | 0.005145 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000985 |
BRD-K43389675-001-02-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.062378 | 8.362978 | 0.649817 | 0.847799 | 2.069414 | 2.102661 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000985 |
BRD-K44227013-001-06-4 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | -0.309653 | 5.028672 | 0.427253 | 0.978131 | 9.552362 | 8.679212 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000985 |
BRD-K44408410-001-17-6 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 0.975025 | 0.382704 | 0.003029 | 0.980997 | 0.001824 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000985 |
BRD-K44827188-001-06-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.588432 | 0.214407 | -0.073503 | 1 | 23.173044 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000985 |
BRD-K46386702-001-02-1 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.382231 | 6.284191 | 0.400944 | 1 | 0.74789 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000985 |
BRD-K49328571-001-15-0 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.952994 | 0.604735 | 0.401845 | 1 | 0.303277 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000985 |
BRD-K49350383-001-14-5 | ACH-000985 | LS411N_LARGE_INTESTINE | MTS010 | 1 | 1.945678 | 4.296117 | 0.453179 | 1 | 0.205487 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000985 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.